129 related articles for article (PubMed ID: 37717601)
1. Metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality among adults in the United States.
Kim D; Wijarnpreecha K; Cholankeril G; Ahmed A
J Hepatol; 2024 Feb; 80(2):e79-e81. PubMed ID: 37717601
[No Abstract] [Full Text] [Related]
2. Are there all-cause mortality differences between metabolic dysfunction-associated steatotic liver disease subtypes?
Li M; Xie W
J Hepatol; 2024 Feb; 80(2):e53-e54. PubMed ID: 37516204
[No Abstract] [Full Text] [Related]
3. BMI status and its changes across adulthood in relation to all-cause mortality in metabolic dysfunction-associated steatotic liver disease.
Sun Z; Liu M; Guo J; Wang S; Jin H
J Hepatol; 2024 May; 80(5):e197-e199. PubMed ID: 38242323
[No Abstract] [Full Text] [Related]
4. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
[TBL] [Abstract][Full Text] [Related]
5. Nutrients associated with metabolic dysfunction-associated steatotic liver disease.
Jeong S
J Hepatol; 2024 Feb; 80(2):e81-e82. PubMed ID: 37717600
[No Abstract] [Full Text] [Related]
6. Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.
Iruzubieta P; Santos-Laso A; Arias-Loste MT; Calleja JL; Crespo J
J Hepatol; 2024 Mar; 80(3):e121-e123. PubMed ID: 37898349
[No Abstract] [Full Text] [Related]
7. Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction-associated steatotic liver disease.
Manikat R; Ahmed A; Kim D
Aliment Pharmacol Ther; 2024 Apr; 59(7):893-895. PubMed ID: 38462684
[No Abstract] [Full Text] [Related]
8. Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction-associated steatotic liver disease-authors' reply.
Verma N; De A; Duseja A
Aliment Pharmacol Ther; 2024 Apr; 59(7):896-897. PubMed ID: 38462705
[No Abstract] [Full Text] [Related]
9. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.
Ochoa-Allemant P; Marrero JA; Serper M
Hepatol Commun; 2023 Dec; 7(12):. PubMed ID: 38051551
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Assessing advanced fibrosis in metabolic-associated steatotic liver disease-The MAFLD fibrosis score.
Sharpton S
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1234-1235. PubMed ID: 37986594
[No Abstract] [Full Text] [Related]
11. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Assessing advanced fibrosis in metabolic-associated steatotic liver disease-the MAFLD fibrosis score. Authors' reply.
Cheung JTK; Chan WK; Zheng MH; Wong VW
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1236-1237. PubMed ID: 37986596
[No Abstract] [Full Text] [Related]
13. Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study.
Han E; Lee BW; Kang ES; Cha BS; Ahn SH; Lee YH; Kim SU
Metabolism; 2024 Mar; 152():155789. PubMed ID: 38224909
[TBL] [Abstract][Full Text] [Related]
14. Risk of binge eating disorder in patients with metabolic dysfunction-associated steatotic liver disease.
Brodosi L; Stecchi M; Marchignoli F; Lucia E; Magnani L; Guarneri V; Petroni ML; Marchesini G; Pironi L
Eat Weight Disord; 2023 Dec; 28(1):100. PubMed ID: 38055131
[TBL] [Abstract][Full Text] [Related]
15. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors.
Danaei G; Ding EL; Mozaffarian D; Taylor B; Rehm J; Murray CJ; Ezzati M
PLoS Med; 2009 Apr; 6(4):e1000058. PubMed ID: 19399161
[TBL] [Abstract][Full Text] [Related]
16. Applying proteomics in metabolic dysfunction-associated steatotic liver disease: From mechanism to biomarkers.
Zhang X; Li X; Xiong X
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102230. PubMed ID: 37931846
[TBL] [Abstract][Full Text] [Related]
17. Increasing Mortality Among Patients With Diabetes and Chronic Liver Disease From 2007 to 2017.
Kim D; Cholankeril G; Kim SH; Abbasi F; Knowles JW; Ahmed A
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):992-994. PubMed ID: 31220638
[TBL] [Abstract][Full Text] [Related]
18. [Metabolic steatotic liver disease: the move towards an inclusive definition].
Zampaglione L; Marello N; Petignat PA
Rev Med Suisse; 2024 Feb; 20(860):311-315. PubMed ID: 38323767
[TBL] [Abstract][Full Text] [Related]
19. Normal weight and central obesity as predictors of increased all-cause mortality in metabolic dysfunction associated steatotic liver disease.
Chen J; Zhou H; Liu K
J Hepatol; 2024 Apr; 80(4):e143-e145. PubMed ID: 38101754
[No Abstract] [Full Text] [Related]
20. [Discussion from metabolism to fatty liver disease: rethinking the origin of disease and the endpoint of new drugs or metabolic dysfunction-associated steatotic liver disease].
Xue F; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):785-788. PubMed ID: 37723057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
